Replies to post #19526 on Titan Medical Inc (TMDIF)

[Daktari]

Let me try this AGAIN:

SPORT and Surgibot are totally different. Surgibot is a conduit that you can pass long flexible surgical instruments through to perform SS surgery. SPORT is 2 parallel robot arms (Da Vinci and all other surgical robots are serial robots similar to those used in other industries). These parallel robot arms are the first and only to ever be used in surgery. They are controlled by a computer and separate surgeon console. The guy your worried knows everything about cardiac stents and very little about general surgery or robotic surgery. Have another Xanax.

[longtermgems]

I kind of just had a revelation after reading your posts about Paul L going to XiMedica and the new vision of Ximedica

I will admit that when I first read the Paul L/Ximedica news a few months back, I seriously thought there was a conflict of interest and TITXF had a new disadvantage because The chairman of TRXC could just hinder/Sabotage the development/production of the SPORT due to the competitive nature between the two companies (both developing a similar product targeting the exact same customers with the surgibot out an entire year prior to the sport).

However, shortly after reading that news, after considerable though, I determined that this was no conflict of interest for either companies and no such sabotage would occur to TITXF. Ximedica just recapitalized under a much more attractive payout scheme for the founders and is now leveraging this new recapitalization to grow on a global scale.

Your post made me realize that TRXC may utilize XiMedica for high volume production once the Surgibot rolls out in late 2015/early 2016, especially given that the chairman of TRXC, Paul L, has a serious financial stake and amount of time he has put into TRXC (years and years and years). Thanks for helping me make that connection!

If you listen to the TRXC CEO interview I posted the other week, you will learn that TRXC never fully went ahead with the commercialization of the spider because they already received a lot of initial feedback from surgeons use of their product. The feedback made them realize that instead of moving forward with a full scale launch of the SPIDEr, they should "roboticize the back end" and create that recurring revenue business model which led to the development of the surgibot.

Todd Pope said that this decision was a tough sell to the board, who were already eager to launch the spider on a fully commercialized scale. So Paul L is super eager to get this surgibot rolling out in high volumes, and I think he just made the investment in Ximedica a few months back to specifically prepare TRXC for it's surgibot launch in the coming year. All my speculation, and opinion.

Also, Todd Popes explanation that the company did not go through with a full scale launch of the SPIDER and instead decided to develop the Surgibot explains why the company only sold 4,000 spider systems, which has been one of the big bashing points for TRXC by TITXF investors.